StockNews.AI
GILD
StockNews.AI
41 days

AHF: Gilead's Greed Costs Latin America HIV Protection

1. AHF criticizes Gilead for high lenacapavir prices in Latin America. 2. Gilead's procurement deal excludes most LAC countries from affordable access.

2m saved
Insight
Article

FAQ

Why Bearish?

Negative public perception and criticism can impact future sales and investments, reminiscent of past pricing controversies affecting GILD.

How important is it?

The criticism from AHF could potentially harm Gilead's reputation and limit market opportunities in Latin America.

Why Short Term?

Immediate backlash can affect GILD's stock price, leading to a short-term negative impact.

Related Companies

GILDBMYMRK
MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir. Today's announcement of a pricing and procurement deal between Gilead and the Global Fund to Fight AIDS, Tuberculosis and Malaria leaves most countries in the region out, forcing them to negotiate individually and in secrecy. “Once again, Latin America and the Caribbean.

Related News